Lundbeck starts phase II trial in Alzheimer

COPENHAGEN Nov 27 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO) said on Friday it would start clinical phase II trials with drug candidate Lu AE58054 as augmentation treatment in Alzheimer's disease.

"The purpose of this study is to investigate if Lu AE58054 after 24 weeks improves cognition and functional outcomes in patients with moderate Alzheimer's disease that are already in treatment with donepezil," Lundbeck said in a statement.

In November 2008, Lundbeck initiated a clinical phase II trial with Lu AE58054 in schizophrenia.

Lundbeck currently generates the majority of its revenue from Cipralex, sold in the United States as Lexapro. (Editing by Dan Lalor) ((Copenhagen newsroom, tel: +45 33969649, e-mail: copenhagen.newsroom@thomsonreuters.com))